Browsing Clinical Studies by publication type "Thesis or Dissertation"
Now showing items 1-20 of 22
-
Applications of liquid biopsies in metastatic castration resistant prostate cancer
(Institute of Cancer Research (University Of London), 2020-02-29)Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ... -
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ... -
ctDNA guided diagnosis and management of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-07-05)Gastrointestinal (GI) cancers including pancreatic (PC), biliary tract (BTC) and colorectal cancers (CRC) rely on a tissue biopsy through invasive procedures such as endoscopies and colonoscopies. Timely diagnosis of these ... -
Deciphering evolutionary trajectories in hereditary renal cell carcinomas
(Institute of Cancer Research (University Of London), 2024-01-16)Establishing the limits of predictability in cancer evolution has significant implications for precision medicine. Clear cell renal cell carcinoma (ccRCC) follows highly deterministic evolutionary pattern with conserved ... -
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30) -
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ... -
Dynamic predictive joint models to characterise localised prostate cancer prognosis after radiotherapy
(Institute of Cancer Research (University Of London), 2023-09-19)This thesis aims to develop and validate dynamic predictive joint models (JMs) to characterise the prognosis of patients with localised prostate cancer who are treated with moderately hypofractionated radiotherapy with ... -
Exploring novel approaches to metastatic heterogeneity and clonal evolution
(Institute of Cancer Research (University Of London), 2021-12-31)Background Alternative methods are required to optimise the clinical insights that may be derived from studies of cancer evolution and heterogeneity. Profiling a single biopsy of tumour tissue underestimates potential ... -
Exploring tumour evolution through single-cell sequencing
(Institute of Cancer Research (University Of London), 2023-10-24)Tumours are composed of heterogeneous populations of cells which, under the pressure of the host and external treatments, evolve across time and space. Recent advances in next-generation sequencing technologies have ... -
Identification of biomarkers to predict differential response to therapeutic agents in advanced triple negative breast cancer
(Institute of Cancer Research (University Of London), 2024-01-16)Patients with triple negative breast cancer (TNBC) tend to have poor outcomes compared to other subtypes, and this is historically due to a lack of targeted therapies for these patients. PARP inhibitors have recently been ... -
Identifying predictive and prognostic markers in localised oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2022-11-23)The survival of patients with localised oesophagogastric (OG) cancer is poor even with multimodality therapy and modern surgical techniques. The need to identify robust but easily-reproducible prognostic and predictive ... -
Improving outcomes for the lung cancer patient with impaired lung function
(Institute of Cancer Research (University Of London), 2021-03-31)Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ... -
Improving outcomes in older women with ovarian cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Background: Older women have disproportionately poorer survival outcomes for ovarian cancer. Sarcopenia, the loss of muscle mass and density is of interest as a potential non-invasive biomarker of frailty. Little is ... -
Molecular subtypes of cancer-associated fibroblasts and their regulation of the tumour microenvironment in pancreatic ductal adenocarcinoma.
(Institute of Cancer Research (University Of London), 2024-03-21)Pancreatic Ductal Adenocarcinoma (PDAC) remains a leading cause of cancer-related deaths, with a 5-year survival rate of less than 10 % in Western countries. Transcriptomic analysis of PDAC in the last decade has unearthed ... -
Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials
(Institute of Cancer Research (University Of London), 2020-01-31)Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ... -
Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer
(Institute of Cancer Research (University Of London), 2019-12-31)KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ... -
Precision genomics for prostate cancer patient stratification
(Institute of Cancer Research (University Of London), 2020-10-31)Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ... -
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ... -
The role of cancer-associated fibroblasts in altering signal transduction and drug resistance in KRAS mutated cancers
(Institute of Cancer Research (University Of London), 2023-01-04)KRAS is commonly mutated in solid tumours but effective treatment is limited due to resistance. Cancer-associated fibroblasts (CAFs) are a key tumour microenvironment component but how it interacts with KRAS mutant-cancer ... -
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...